ArticleInternational journal of cardiology. Congenital heart disease2022
Association of plasma biomarkers and interstitial myocardial fibrosis in fontan population: A machine learning approach.
Article in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic Remodeling in Fontan Circulation Associated with Fibrosis and Time-Dependent Immune-Metabolic Alteration.International journal of molecular sciences · 2026Article
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
- Circulating Biomarkers in Failing Fontan Circulation: Current Evidence and Future Directions.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial fibrosis is a common final pathway in many myocardial diseases. Circulating biomarkers are recognized in heart failure management as potential treatment targets. The current study sought to evaluate the association between biomarkers of myocardial fibrosis and myocardial fibrosis using machine learning techniques. Methods and Results: The permutation-based feature importance and the cooperation network among important features in random forest algorithm were applied to evaluate the relationship of each biomarker to extracellular volume fraction (ECV). A total of 25 Fontan patients were included in the study with multiple serum biomarkers obtained at the time of CMR. The mean age at the time of assessment was 16.3 ± 6.8 years with the mean duration of Fontan circulation of 13.0 ± 6.3 years. Lateral tunnel was the most common Fontan type (52%), and the majority (72%) had a systemic left ventricle. The mean ECV was 28 ± 5%. Among different types of matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP), our study found that MMP-10, and TIMP-1 were the most strongly associated with cardiac fibrosis measured by ECV. Conclusions: TIMP-1 and MMP-10 are circulating biomarkers that may represent promising targets for the prevention and treatment of myocardial fibrosis in Fontan circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.